- Home
- CMMB
CMMB
Chemomab Therapeutics Ltd.
as 01-22-2025 4:00pm EST
| Founded: | 2004 | Country: | Israel |
| Employees: | N/A | City: | TEL AVIV |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $7.50 | AVG Volume (30 days): | 113.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.46 - $2.55 | Next Earning Date: | 03-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Chemomab Therapeutics Ltd. News
CMMB Breaking Stock News: Dive into CMMB Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 months ago
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
GlobeNewswire
2 months ago
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis
GlobeNewswire
2 months ago
Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
3 months ago
Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update
GlobeNewswire
3 months ago
Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024
GlobeNewswire
4 months ago
Chemomab Therapeutics to Present at October 2024 Investor Conferences
GlobeNewswire
5 months ago
Chemomab Therapeutics to Present at September 2024 Investor Conferences
GlobeNewswire
5 months ago
Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Compare CMMB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CMMB Chemomab Therapeutics Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.